ArticleNature immunology2021
Distinct metabolic programs established in the thymus control effector functions of γδ T cell subsets in tumor microenvironments.
Open access · greenAbstract read
In one paragraph
Article in Nature immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 135 papers.
0numbers the graph read from it
0cells of the map it votes in
135citing papers in PubMed
12.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
135 citing papers in PubMed, 190 citations in OpenAlex.
- Crosstalk between the microbiota and intestinal γδ T cell compartments in health and IBD.Gut microbes · 2026Review
- Glutamate attenuates the ILC2 response and allergic airway inflammation via the kainate receptor GluK2.Cellular & molecular immunology · 2026Article
- Metabolic immune checkpoints (MICs) in cancer: from molecular mechanisms to challenges and opportunities in clinical translation.Signal transduction and targeted therapy · 2026Review
- Article
- Enrichment of CD4iScience · 2026Article
- Boosting T cell antioxidant capacity: A strategic approach to overcome immunosuppression in solid tumors.Redox biology · 2026Review
- γδ T cells and cancer.The Journal of clinical investigation · 2026Review
- Unconventional T cells in urological cancers: catch them if you can.Nature reviews. Urology · 2026Review
- Regulatory T cells sabotage anti-tumor γδ T cells by creating IL-2-deficient environments.The Journal of experimental medicine · 2026Article
- Aryl hydrocarbon receptor deficiency triggers the activation of γδT17 cells to exacerbate autoimmune inflammation.Science advances · 2026Article
- Poorly perfused tumor regions harbor T cells with a glucose-dependent effector phenotype.EMBO reports · 2026Article
- Effector Vδ1 γδ T cells mediate anti-tumor immunity and are reprogrammed by imatinib in human gastrointestinal stromal tumor.Research square · 2026Article
- Harnessing the potential of γδ T cells through engineering and combination treatment for cancer therapies.Nature communications · 2026Review
- Blockade of NKp46⁻ CCR6⁻ ILC3 autophagy protects against necrotizing enterocolitis by restoring energy metabolism balance in mice.Nature communications · 2026Article
- γδ T cell-stromal networks modulate matrix composition and vascularity in foreign body response.Nature communications · 2026Article
- Ketogenic diet synergistic reprogramming of both host and microbiome promotes tissue regeneration.bioRxiv : the preprint server for biology · 2026Article
- Revisiting T cells: Innate actions and emerging links to innate memory response.Journal of immunology (Baltimore, Md. : 1950) · 2026Review
- Glycolysis in the tumor microenvironment shapes dendritic cell function and antitumor immunity.Frontiers in immunology · 2026Review
- Metabolic control of innate-like T cells.Nature reviews. Immunology · 2026Review
- Article
75 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 5 institutions in 5 countries.
Noella Lopes *Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
Claire McIntyre *Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-2489-7724
Stefania Martin *Blizard Institute, Barts and The London School of Medicine, Queen Mary University of London, London, UK.
Mathilde Raverdeau *Trinity Biomedical Science Institute, Trinity College Dublin, Dublin, Ireland.ORCID http://orcid.org/0000-0002-6088-6902
Nital SumariaBlizard Institute, Barts and The London School of Medicine, Queen Mary University of London, London, UK.
Ayano C KohlgruberBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-6758-3966
Gina J FialaInstituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.ORCID http://orcid.org/0000-0002-8226-5584
Leandro Z AgudeloMIT Computer Science and Artificial Intelligence Laboratory, Cambridge, MA, USA.
Lydia DyckTrinity Biomedical Science Institute, Trinity College Dublin, Dublin, Ireland.
Harry KaneBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Aaron DouglasTrinity Biomedical Science Institute, Trinity College Dublin, Dublin, Ireland.
Stephen CunninghamTrinity Biomedical Science Institute, Trinity College Dublin, Dublin, Ireland.
Hannah PrendevilleTrinity Biomedical Science Institute, Trinity College Dublin, Dublin, Ireland.ORCID http://orcid.org/0000-0003-3731-4372
Roisin LoftusTrinity Biomedical Science Institute, Trinity College Dublin, Dublin, Ireland.
Colleen CarmodyBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Philippe PierreAix Marseille Université, CNRS, INSERM, CIML, Centre d'Immunologie de Marseille-Luminy, Marseille, France.ORCID http://orcid.org/0000-0003-0863-8255
Manolis KellisMIT Computer Science and Artificial Intelligence Laboratory, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-7113-9630
Michael BrennerBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-6202-8445
Rafael J ArgüelloAix Marseille Université, CNRS, INSERM, CIML, Centre d'Immunologie de Marseille-Luminy, Marseille, France.ORCID http://orcid.org/0000-0001-9785-3883
Bruno Silva-Santos *Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.ORCID http://orcid.org/0000-0003-4141-9302
Daniel J Pennington *Blizard Institute, Barts and The London School of Medicine, Queen Mary University of London, London, UK. d.pennington@qmul.ac.uk.ORCID http://orcid.org/0000-0001-7889-9923
Lydia Lynch *Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Brigham and Women's Hospital · USTrinity College Dublin · IEQueen Mary University of London · GBUniversity of Lisbon · PTCentre National de la Recherche Scientifique · FR
Funding
Dissection of endosomal trafficking mechanisms in Alzheimer's DiseaseRF1AG062377 · NIA · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI TSAI, LI-HUEI · 2018 to 2018
$3.6MConstruction of an Integrated Immune-Vascular Brain - Chip as a Platform for the Study, Drug Screening, and Treatments of Alzheimer's DiseaseUH3NS115064 · NINDS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BLANCHARD, JOEL WILLIAM, KELLIS, MANOLIS · 2021 to 2023
$3.5MSupplement: Immunometabolic and epigenetic effects of obesity on innate immune surveillance in cancerR01AI134861 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI LYNCH, LYDIA · 2018 to 2022
$2.9MConstruction of an integrated immune - vascular brain - chip as a platform for the study, drug screening, and treatments of Alzheimer's diseaseUG3NS115064 · NINDS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BLANCHARD, JOEL WILLIAM, KELLIS, MANOLIS · 2019 to 2020
$2.5MInterpreting non-coding variants using epigenomics, regulatory models, & validation experimentsR01HG008155 · NHGRI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI KELLIS, MANOLIS · 2015 to 2017
$2.3MComprehensive Lab Animal Monitor System (CLAMS) for the Study of Mouse MetabolismS10OD020100 · OD · BRIGHAM AND WOMEN'S HOSPITAL · PI BANKS, ALEXANDER · 2015 to 2015
$419kBiotechnology and Biological Sciences Research Council BB/R017808/1European Research Council 646701Medical Research Council 1504814NHGRI NIH HHS R01 HG008155NIAID NIH HHS R01 AI134861NIA NIH HHS RF1 AG062377NIH HHS S10 OD020100NINDS NIH HHS UG3 NS115064NINDS NIH HHS UH3 NS115064Wellcome Trust 092973Wellcome Trust 092973/Z/10/Z
Abstract
Metabolic programming controls immune cell lineages and functions, but little is known about γδ T cell metabolism. Here, we found that γδ T cell subsets making either interferon-γ (IFN-γ) or interleukin (IL)-17 have intrinsically distinct metabolic requirements. Whereas IFN-γ
Indexed as
Energy MetabolismTumor MicroenvironmentAnimalsBreast NeoplasmsCell LineageCell Line, TumorColonic NeoplasmsFemaleGlucoseGlycolysisHumansImmunotherapy, AdoptiveInterferon-gammaInterleukin-17Lipid MetabolismLymphocytes, Tumor-InfiltratingGlucoseIFNG protein, mouseInterferon-gammaInterleukin-17Receptors, Antigen, T-Cell, gamma-delta
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.